|

Datopotamab Deruxtecan (Dato-DXd) Clinical Trials

5 actively recruiting trials across 4 locations

▲ +1 trial since June 2026

Also known as: DS-1062a, Datroway

Pipeline

Phase 2: 2Phase 3: 1Phase 4: 1Phase 1/2: 1

Top Sponsors

  • AstraZeneca4
  • Queen Mary University of London1

Indications

Other1 trial

Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
Phase 2

Chandler, Arizona1 trial

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site

Phase 3

Tucson, Arizona1 trial

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

Research Site

Phase 4

La Jolla, California1 trial

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Research Site

Phase 1/2

Los Angeles, California1 trial

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Research Site

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.